Publications by authors named "C Iwao"
Objectives: There is limited consensus on resectability criteria for Stage IIIA-N2 non-small cell lung cancer (NSCLC). We examined the patient characteristics, N2 status, treatment decisions, and clinical outcomes according to the treatment modality for Stage IIIA-N2 NSCLC in Japan.
Materials And Methods: Patients with Stage IIIA-N2 NSCLC in Japan were consecutively registered in the SOLUTION study between 2013 and 2014.
Background: T-SPOT.TB, one of the screening tests for latent tuberculosis infection (LTBI), yields invalid results in human T-cell leukemia virus type 1 (HTLV-1)-positive patients with rheumatoid arthritis. However, the detailed mechanisms behind this invalidation are unclear.
View Article and Find Full Text PDFArticle Synopsis
- Treating cryptococcosis in HIV patients is tough due to limited antifungal options and lack of approval for isavuconazole in the US and Europe.
- A case study follows a Japanese man who developed cryptococcal meningitis, relapsed after fluconazole treatment, and was later diagnosed with disseminated cryptococcosis.
- He was successfully treated with a combination of isavuconazole and liposomal amphotericin B, suggesting that isavuconazole may be a viable treatment option, warranting further clinical trials to ensure effectiveness and safety.*
Article Synopsis
- Human granulocytic anaplasmosis (HGA) is a rare tick-borne disease in Japan, with only seven reported cases, including a significant one involving a 61-year-old female farmer.
- The patient presented with symptoms like rash, fever, and rhabdomyolysis, and testing revealed elevated levels of creatinine and creatinine kinase, indicating muscle damage, alongside a tick bite.
- Despite initial treatments for suspected Japanese spotted fever, the diagnosis of HGA was confirmed through antibody detection, highlighting the need for better diagnostic systems and awareness of HGA in Japan, especially for patients with outdoor activity history.
Objectives: The objectives of this study were to retrospectively investigate the patient characteristics, treatment patterns, healthcare resource utilization (HCRU), and healthcare costs related to management of neurofibromatosis type 1 (NF1) in Japan.
Methods: Cohorts of NF1 patients with or without plexiform neurofibromas (PN) were identified from the Medical Data Vision database in 2008-2019. Baseline characteristics, NF1 medications, HCRU, and associated costs were assessed using descriptive statistics.